Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma
Pourmaleki M, Jones C, Ariyan C, Zeng Z, Pirun M, Navarrete D, Li Y, Zhang M, Nandakumar S, Campos C, Nadeem S, Klimstra D, Temple-Oberle C, Brenn T, Lipson E, Schenk K, Stein J, Taube J, White M, Traweek R, Wargo J, Kirkwood J, Gasmi B, Goff S, Corwin A, McDonough E, Ginty F, Callahan M, Schietinger A, Socci N, Mellinghoff I, Hollmann T. Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. Cancer Immunology Research 2022, 10: 303-313. PMID: 35013003, PMCID: PMC8898286, DOI: 10.1158/2326-6066.cir-21-1083.Peer-Reviewed Original ResearchConceptsCD8+ T cellsT cellsUntreated lesionsTumor cellsCohort of metastatic melanoma patientsProliferating CD8+ T cellsPredictive biomarkers of treatment responseExpression of PD-1MHC class I expressionBiomarkers of treatment responseMetastatic melanoma patientsB cell aggregatesResponse to IL2Class I expressionExpression of IFNGIL2 therapyPD-1Cancer immunotherapyTumor regressionMelanoma patientsLAG-3Tim-3IL2 responsivenessInjected lesionsPredictive biomarkers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply